Weekly company factor report
CUE Valuation, Quality and Momentum
Cue Biopharma
Current comparison
Latest company comparison
The scores rank this company against other measured companies in the selected market. Open each section to check the figures behind them.
Current factor profile
Measured price variability is high and should be considered separately from the return figures.
Strong price performance, high variability
Price performance ranks 82/100, but one-year volatility is 225%. The price path has been less stable than the headline return.
Four main ranks
Company profile
Completed weekly snapshots
How the ranks have changed
Ready-made approaches
Which screens include this company
Passing a screen means the latest completed snapshot meets that screen’s published rules. It is not a recommendation.
Continue the research
Check the supporting evidence
Open the price record, technical position, market group or other company research that is available for CUE.
Price against company results
Value
A higher value rank means the shares are cheaper on the combined definitions relative to this market. Negative earnings or cash flow need separate attention.
Current reading
Free-cash-flow yield is negative at -25.1%. The six-measure value score is 90.00000000/100, indicating a high valuation across the combined measures; lower is cheaper.
Value measures compared
Raw multiples and yields
Valuation history is not yet established
No positive earnings base is available in the accepted history. P/E is not meaningful while earnings are zero or negative.
15 earlier weekly observations had no valid positive-earnings P/E.
Research path
How to test this valuation
A low valuation is a starting point. These checks show whether the earnings base, cash flow and completed price record support it.
Profitability, cash and balance sheet
Financial strength
The rank combines several company measures. The chart and figures below keep profitability, leverage and cash conversion visible separately.
Current reading
Debt to equity is 12.29; leverage contributes to both returns and balance-sheet risk.
Financial measures compared
Profitability and leverage
Completed returns and variability
Price performance and risk
Returns show direction; volatility and drawdown show how uneven the path has been. Both are based on completed prices.
Current reading
The 12-month return excluding the latest month is 54%. Near-term vol (553%) is expanding vs long-term (225%) — risk is increasing.
Returns over several periods
Recent and one-year volatility
How long the current readings have persisted
| Measure | Current | Current run | Direction |
|---|---|---|---|
| OS Composite | 0.350 | Unchanged for 0 snapshots | improving |
| Value %ile | 0.090 | Unchanged for 15 snapshots | deteriorating |
| Quality %ile | 0.670 | Unchanged for 0 snapshots | improving |
| Momentum %ile | 0.820 | Unchanged for 5 snapshots | improving |
| F-Score | 4.000 | Unchanged for 15 snapshots | stable |
| Confidence | 0.788 | Unchanged for 15 snapshots | improving |
| Volatility | 2.252 | Unchanged for 15 snapshots | improving |
Like-for-like context
Sector comparison
The company is compared with measured companies in Healthcare for the same completed factor week.
Company against sector
Valuation distance from sector
| Company | Combined | Value | Financial strength | Price performance |
|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals Inc | 99.0 | 97.0 | 97.0 | 98.0 |
| NUTX Nutex Health Inc | 99.0 | 94.0 | 98.0 | 95.0 |
| CGEN Compugen | 98.0 | 85.0 | 96.0 | 93.0 |
| THC Tenet Healthcare Corporation | 98.0 | 92.0 | 92.0 | 82.0 |
| AMN AMN Healthcare Services Inc | 97.0 | 96.0 | 65.0 | 93.0 |
| HRMY Harmony Biosciences Holdings | 97.0 | 90.0 | 98.0 | 76.0 |
| MD Mednax Inc | 97.0 | 88.0 | 87.0 | 90.0 |
| RIGL Rigel Pharmaceuticals Inc | 96.0 | 87.0 | 95.0 | 74.0 |
Reported company accounts
Company figures
Quarterly and annual figures are kept separate. The dates below show the latest accepted reporting periods.
Quarterly figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Annual figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Definitions and source checks
Measures and data
Each figure is shown with its plain definition. Percentile ranks compare the company with the selected market for the same completed week.
Value measures · Price compared with earnings, sales, assets and cash flow
Financial strength · Profitability, cash conversion and balance-sheet measures
Price performance · Completed price returns over several periods
Growth and stability · Revenue, earnings history and capital returned to shareholders
Combined value measures · Several valuation measures ranked together; 1 is cheapest
Capital use and company classification · Funding, distributions and company-size classifications
Company research path · week ending 11 Sep 2026
Price strength is running ahead of the valuation test
The company record passes, but the relative valuation is not yet compelling.
The path reads company results, valuation, completed price evidence and risk in that order. A later strength does not cancel an earlier weakness.
- ✓ Data readyPassed · 100/100 Published factors, company figures and completed prices are available.
- ✓ Company recordPassed · 62/100 Checks profitability, cash support, balance-sheet measures and their direction.
- 3 Relative valueNeeds more evidence · 9/100 Checks whether the current valuation compares well with the selected market.
- 4 Market supportNot reached · 81/100 Checks completed price performance, relative strength, trend and buying pressure.
- 5 Setup and riskNot reached · 52/100 Checks whether the price structure is usable without ignoring volatility or drawdown.
- 6 Full reviewNot reached Open the supporting company, market and risk research before making a decision.
Evidence used now
What moves the research path
Each block opens the report section containing the figures behind the score.
- Financial-strength rank 67/100
- F-Score 4/9
- 5 usable annual periods
- Value rank 9/100
- P/E Not available
- Free-cash-flow yield -25.1%
- Price-performance rank 82/100
- Six-month return +237.7%
- Relative strength +0.3
- Stage 1 · Basing
- Stage 1 · Basing
- Price at -21.9% of its 52-week high
- Completed price structure and risk combined
- One-year volatility 225.2%
- Recent volatility 553.2%
- 12-month drawdown -77.4%
Completed factor weeks
How the evidence has moved
All four lines are higher-is-better market ranks on the same 0–100 scale.
What the current evidence supports
- Company record scores 62/100.
- Market support scores 81/100.
What still needs attention
- Relative value scores 9/100.
- Setup scores 52/100.
- Risk check scores 25/100.
Next check
Compare the valuation measures with the sector and check what is driving the low rank.
This path uses completed records and is recalculated with each published factor week. It is a research sequence, not a trade instruction.
Supporting Sharemaestro research
Continue with the available evidence
Only research pages with data for CUE are shown.